Rituximab Therapy for Epstein-Barr Virus–Related Chronic Hepatitis Following Living Donor Kidney Transplantation  Kazuhide Ohta, MD, PhD, Masaki Shimizu, MD, PhD, Akiko Nakai, MD, Tomoko Toma, MD, PhD, Yoshihito Kasahara, MD, PhD, Chihiro Arii, MS, Akihiro Yachie, MD, PhD, Takeshi Kawamura, MD, PhD, Atsushi Aikawa, MD, PhD, Akira Hasegawa, MD, PhD, Kazutaka Sato, MD, PhD, Hitoshi Yokoyama, MD, PhD, Isao Ishikawa, MD, PhD, Shoichi Koizumi, MD, PhD  American Journal of Kidney Diseases  Volume 48, Issue 6, Pages 986-989 (December 2006) DOI: 10.1053/j.ajkd.2006.09.010 Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

Fig 1 Hematoxylin and eosin staining of the liver biopsy specimen (A) before and (B) after rituximab treatment. Immunohistochemistry shows (C) CD3+ T cells and (D) CD20+ B cells. (E) EBV-infected cells were detected by means of EBER-1 in situ hybridization. American Journal of Kidney Diseases 2006 48, 986-989DOI: (10.1053/j.ajkd.2006.09.010) Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

Fig 2 Rituximab therapy and clinical course. American Journal of Kidney Diseases 2006 48, 986-989DOI: (10.1053/j.ajkd.2006.09.010) Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions